Kymab was founded by Professor Allan Bradley, FRS, in 2010, based on developments in his laboratory at the Wellcome Trust Sanger Institute.
We raised $30m of equity financing in 2010 from the Wellcome Trust Investment Division to enable the development of our antibody-delivery platform and create a portfolio of therapeutic assets.
Using embryonic stem cell technology, Professor Bradley’s team developed the Kymouse™ platform, which encompasses the entire diversity of the B lymphocyte component of the human immune system.
In a paper published in Nature Biotechnology in 2014 (PDF version here), our researchers showed that our technology yields an antibody library constituted from 100 trillion different antibodies. From this deep library, we can select rare high-quality antibodies that can be developed into therapeutics.
Since we were founded, we have built strong executive and leadership teams, recruiting people who have a proven track record in the key areas of antibody therapeutics, disease research, drug development, business development and financial control.
In 2014, the Bill and Melinda Gates Foundation and The Wellcome Trust made a Series B investment of $40 million in Kymab, followed by further investment in 2015 from Woodford Patient Capital Trust plc and Malin Corporation, which raised $50 million. In November 2016, Kymab secured US$100 million (£81 million) in Series C financing, led by new investors ORI Healthcare Fund L.P., with participation by Shenzhen Hepalink Pharmaceutical Co., Ltd, as well as follow-on investments from existing shareholders.
Kymab has around 100 staff and is headquartered on the Babraham Research Campus, three miles from Cambridge Biomedical Campus, the MRC Laboratory of Molecular Biology and Addenbrooke’s Teaching Hospital.